.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Drug patents in 130+ countries

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Cantor Fitzgerald
Cerilliant
Federal Trade Commission
McKinsey
Novartis
Deloitte
Fish and Richardson
Baxter
Healthtrust
Daiichi Sankyo

Generated: September 23, 2017

DrugPatentWatch Database Preview

ZEGERID OTC Drug Profile

« Back to Dashboard

What is the patent landscape for Zegerid Otc, and what generic Zegerid Otc alternatives are available?

Zegerid Otc is a drug marketed by Bayer Healthcare Llc and is included in two NDAs. There are six patents protecting this drug and one Paragraph IV challenge.

This drug has sixty-two patent family members in twenty-four countries.

The generic ingredient in ZEGERID OTC is omeprazole; sodium bicarbonate. There are one hundred and twenty-one drug master file entries for this compound. Twenty-one suppliers are listed for this compound. Additional details are available on the omeprazole; sodium bicarbonate profile page.

Summary for Tradename: ZEGERID OTC

Patents:6
Applicants:1
NDAs:2
Suppliers / Packagers: see list1
Bulk Api Vendors: see list2
Clinical Trials: see list78
Patent Applications: see list8
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:ZEGERID OTC at DailyMed
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Bayer Healthcare Llc
ZEGERID OTC
omeprazole; sodium bicarbonate
CAPSULE;ORAL022281-001Dec 1, 2009OTCYesYes► Subscribe► SubscribeYY ► Subscribe
Bayer Healthcare Llc
ZEGERID OTC
omeprazole; sodium bicarbonate
FOR SUSPENSION;ORAL022283-001Jun 17, 2013OTCYesYes► Subscribe► Subscribe ► Subscribe
Bayer Healthcare Llc
ZEGERID OTC
omeprazole; sodium bicarbonate
CAPSULE;ORAL022281-001Dec 1, 2009OTCYesYes► Subscribe► SubscribeYY ► Subscribe
Bayer Healthcare Llc
ZEGERID OTC
omeprazole; sodium bicarbonate
CAPSULE;ORAL022281-001Dec 1, 2009OTCYesYes► Subscribe► SubscribeYY ► Subscribe
Bayer Healthcare Llc
ZEGERID OTC
omeprazole; sodium bicarbonate
CAPSULE;ORAL022281-001Dec 1, 2009OTCYesYes► Subscribe► Subscribe ► Subscribe
Bayer Healthcare Llc
ZEGERID OTC
omeprazole; sodium bicarbonate
FOR SUSPENSION;ORAL022283-001Jun 17, 2013OTCYesYes► Subscribe► Subscribe ► Subscribe
Bayer Healthcare Llc
ZEGERID OTC
omeprazole; sodium bicarbonate
FOR SUSPENSION;ORAL022283-001Jun 17, 2013OTCYesYes► Subscribe► SubscribeY ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: ZEGERID OTC

Paragraph IV activity for: ZEGERID OTC

Drugname Dosage Strength RLD Submissiondate
omeprazole and sodium bicarbonateCapsules20 mg/1100 mgZegerid OTC4/20/2010

Non-Orange Book Patents for Tradename: ZEGERID OTC

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
RE45198Omeprazole solution and method for using same► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: ZEGERID OTC

Country Document Number Estimated Expiration
Canada2594185► Subscribe
Poland367272► Subscribe
Australia2005229686► Subscribe
Poland357144► Subscribe
Eurasian Patent Organization200400966► Subscribe
Canada2594185► Subscribe
European Patent Office1246622► Subscribe
Austria340574► Subscribe
Spain2275650► Subscribe
European Patent Office1414452► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: ZEGERID OTC

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C/GB11/013United Kingdom► SubscribePRODUCT NAME: NAPROXEN AND ESOMEPRAZOLE; REGISTERED: UK PL 17901/0263-0001 20101105
C/GB11/015United Kingdom► SubscribePRODUCT NAME: NAPROXEN AND ESOMEPRAZOLE; REGISTERED: UK PL 17901/0263-0001 20101105
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Express Scripts
Cerilliant
Medtronic
Fish and Richardson
Cipla
McKinsey
Daiichi Sankyo
Moodys
Farmers Insurance
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot